Moderna Inc (NASDAQ:MRNA) shares are trading higher by 4.0% to $43.90 Monday afternoon after the CDC reported a significant rise in acute respiratory illnesses across the U.S., driven by seasonal influenza, COVID-19 and RSV. The CDC highlighted an uptick in healthcare visits linked to these viruses, sparking renewed interest in vaccine manufacturers.
Moderna, a leader in mRNA vaccine technology, could be well-positioned to address this increased demand. The company's COVID-19 vaccine remains a key player in the market, and its pipeline includes combination vaccines targeting COVID-19, RSV, and flu.
Investor sentiment may have also bolstered Moderna’s previous ability to adapt its platform quickly to emerging health threats such as the COVID-19 pandemic, highlighting it as a vital contributor to public health preparedness.
Read Also: Nvidia 5000 Series, Product Updates Make It Top Semiconductor Pick Ahead Of Jensen Huang’s CES Keynote: Analyst
How To Buy MRNA
By now you're likely curious about how to participate in the market for Moderna – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Moderna, which is trading at $43.8 as of publishing time, $100 would buy you 2.28 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
According to data from Benzinga Pro, MRNA has a 52-week high of and a 52-week low of
